NIRCO med‎ > ‎drugs‎ > ‎Antithrombotika‎ > ‎Faktor-Xa-Inhibitoren‎ > ‎indirekte‎ > ‎

fondaparinux

Warnhinweise und Vorsichtsmassnahmen: the risk of HIT is relatively low (2).

Revertieren: administration of rFVIIa (90 µg kg−1) normalized the clot lysis time up to 6 h postadministration. rFVIIa might be a good therapeutic option in patients treated with fondaparinux who develop bleeding complications, since both clot formation as well as fibrinolytic resistance are improved (3).

Eigenschaften/Wirkungen: fondaparinux is a synthetic pentasaccharide that binds to antithrombin, producing a conformational change at the reactive site of antithrombin, to selectively inhibit factor Xa by mechanisms identical to LMWHs, but without affecting thrombin activity (1).

Downloads/links: Guidelines für die Anästhesiologie: sgar.

Referenzen:
  1. Novel Oral Anticoagulants: Implications in the Perioperative Setting. Anesthesiology. 2010;113:726–45: full text | pdf | periop.
  2. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood. 2005;106:3791-3796: full text | pdf.
  3. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost. 2003;1:2368 –73: full text | pdf.